Cytokinetics (CYTK) Stock Skyrockets By 50% In Pre-Market: Make Your Move To Profit

Cytokinetics stock has been having a very unstable market for the last week. The stock was trading at $19.23 as of the last trading session. As of now in the pre-market the stock is skyrocketing by 50%, the price jumped to $29.65. This sudden rise is caused by the company’s announcement of receiving positive results for heart disease treatment.
Results from the second and first two cohorts of the REDWOOD-HCM trial support the initiation of Phase 3 registrational study of CK-3773274 in hypertrophic cardiomyopathy. Results from the first two cohorts of the REDWOOD-HCMM study revealed that treatment with CK-2274 resulted in statistically significant decreases in the average resting heart rate and the post-Valsalve LVOT-G. Most patients treated with CK-274 achieved the target goal of reducing resting LVOT-G by at least 30% at Week 10.

The safety and efficacy of CK-274 in the REDWOOD-HCM trial were generally well tolerated. There were no serious unfortunate moments in the study. In one patient, the left ventricular ejection fraction returned to its baseline within 2 weeks after the end of their treatment.

Want Hot Stocks?    Yes. I Love Them No thanks